Educational model promotes drug discovery skills in undergraduates, suggesting new pathways for future chemists.
The role of the medicinal chemist in the pharmaceutical industry has continued to evolve over the past two decades in the face of globalization and cost reduction strategies. The ever expanding skill set expected of the medicinal chemist as a drug designer with lessening responsibilities in the synthetic realm have led to a re-examination of the training models in academia so as to better prepare the drug discoverer of the future. While such remedies are being developed primarily at top tier academic institutions with medicinal chemistry Ph.D. programs as well as those housing Academic Drug Discovery Centers (ADDCs), smaller institutions with limited resources can also contribute to this effort by exposing undergraduates to the excitement of the drug discovery process through research and coursework. To this end, the PharmaFlight concept is suggested as a practical model for experiential learning in medicinal chemistry. In this modality, undergraduate research students are tasked with determining whether a particular structural feature of a privileged scaffold can be associated with a certain disease state, determine if the information available in the literature can be utilized to develop preliminary structure activity relationships (SARs), and then design and synthesize a PharmaFlight (a collection of 4-6 molecules) based upon a static element or structural motif in the core structure and designed to address gaps in the published literature. Once a slate of candidate molecules has been decided upon, the proposed entities are evaluated for drug-likeness and potential toxicity issues using the free software program SwissADME before synthesis and spectroscopic characterization. When conducted in concert with a biological assay relevant to the targeted disease state, the process completes the design-synthesize-screen iterative cycle which constitutes the drug discovery paradigm. Overall, we propose this PharmaFlight model as both an educational tool for the cultivation of future medicinal chemists and as an approach to small scale academic drug discovery.
No takes yet. Share an insight, caveat, or question.
Kinstedt et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: